Clinical trials: Obsessive-Compulsive Disorder
Obsessive Compulsive Disorder
Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF)
The purpose of the study is to monitor the safety and performance of Reclaim® Deep Brain Stimulation (DBS) Therapy in patients with chronic, severe, treatment-resistant Obsessive Compulsive Disorder.
- Trial name
- NCT01135745
- Testing
- Reclaim® Deep Brain Stimulation
- Where
- 8 sites in Belgium, Germany and 5 more
- Volunteers
- 32 people
- Sponsor
- MedtronicNeuro
Obsessive Compulsive Disorder
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
The objective of the first phase of this study is to evaluate the efficacy of fluvoxamine compared to placebo on change in total score of Japanese version of the Children's Yale-Brown Obsessive Compulsive Scale (JCY-BOCS) 10-item…
- Trial name
- NCT01933919
- Testing
- Fluvoxamine maleate
- Volunteers
- 38 people
- Sponsor
- AbbVie
Obsessive-Compulsive Disorder
A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)
This multicenter, randomized, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of bitopertin in combination with SSRI in participants with obsessive-compulsive disorder.
- Trial name
- NCT01674361
- Testing
- Bitopertin, SSRI
- Where
- 34 sites in United States, Canada
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses
Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy
The purpose of this study is to determine whether AFQ056 as an add on therapy to SSRIs can have beneficial effects by reducing the total score of Y-BOCS (Yale and Brown Obsessive Compulsive Scale) in OCD patients resistant to…
- Trial name
- NCT01813019
- Testing
- AFQ056
- Where
- 15 sites in United States, Bulgaria and 3 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Obsessive-Compulsive Disorder
The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder
The purpose of this clinical study is To verify the long term effectiveness and safety of a bilateral deep brain stimulation (DBS) produced by Beijing PINS Medical Co., Ltd.
- Trial name
- NCT02253472
- Testing
- Deep Brain Stimulation
- Volunteers
- 30 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Obsessive-Compulsive Disorder
Characterize The Modulatory Effects Of Dopamine D2/D3 Receptor Agonist And Antagonist Drugs On Compulsive Behaviors
3 groups of subjects (healthy controls, OCD subjects and stimulant-dependent subjects) will receive pramipexole (1.5 mg, single dose), amisulpride (400 mg, single dose) or placebo in a cross-over, double-blind, placebo-controlled…
- Trial name
- NCT00471588
- Testing
- Pramipexole, Amisulpride
- Where
- United Kingdom
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obsessive-compulsive Disorder
Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder
This study is to assess the efficacy and safety of two doses of ondansetron (0.5 mg and 0.75 mg) relative to placebo when administered twice daily as adjunctive therapy for adult patients with Obsessive-Compulsive Disorder (OCD)…
- Trial name
- NCT01275248
- Testing
- Ondansetron
- Where
- 32 sites in United States, Mexico
- Volunteers
- 130 people
- Sponsor
- Transcept Pharmaceuticals
Obsessive-Compulsive Disorder
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
The purpose of this study is to determine if the combination of naltrexone SR and fluoxetine is more effective in treating the symptoms of obsessive-compulsive disorder (OCD)than either fluoxetine alone or naltrexone SR alone.
- Trial name
- NCT00758966
- Testing
- Fluoxetine 60 mg, Naltrexone 32 mg and fluoxetine 60 mg, Naltrexone SR 32 mg
- Where
- 11 sites in United States
- Volunteers
- 8 people
- Sponsor
- Orexigen Therapeutics, Inc
Obsessive Compulsive Disorder
Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD)
The purpose of this study is to investigate the effect of NPL-2003 on the symptoms of Obsessive Compulsive Disorder (OCD) in an adolescent population.
- Trial name
- NCT00515255
- Testing
- Minocycline
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Neuropharm
Body Dysmorphic Disorders
Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions
Body Dysmorphic Disorder (BDD) is a disabling condition that until recently has been largely ignored. Sufferers of BDD worry excessively and unreasonably about some flaw in their appearance that may be minimal or even…
- Trial name
- BDD (NCT01316627)
- Testing
- Crooked Mirror Externalization Therapy, Mirror Retraining Method
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Westwood Institute for Anxiety Disorders, Inc
Obsessive Compulsive Disorder
Addition of Quetiapine in Obsessive Compulsive Disorder - Westenberg Study
Quetiapine (Seroquel ®), an atypical antipsychotic registered for use in schizophrenia, which has a very low propensity of extrapyramidal and endocrine side-effects, has also been studied as an adjunct in OCD.
- Trial name
- NCT00318539
- Testing
- Quetiapine
- Where
- Netherlands
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Obsessive Compulsive Disorder
Fluvoxamine Maleate in the Treatment of Obsessive-Compulsive Disorder: A Post-marketing Clinical Study in Children and Adolescents
This study is to verify the efficacy of fluvoxamine maleate given for 10 weeks in treatment of children and adolescents with obsessive-compulsive disorder
- Trial name
- NCT00352768
- Testing
- Fluvoxamine maleate
- Where
- 11 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Solvay Pharmaceuticals
Obsessive Compulsive Disorder
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
- Trial name
- NCT00254735
- Testing
- quetiapine fumarate, SSRI/Clomipramine
- Where
- 2 sites in Germany
- Volunteers
- 44 people
- Sponsor
- AstraZeneca